Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Chi-Chung Li, PhD, Brendan Bender, PhD, Shen Yin, PhD, Zao Li, PhD, Cindy Zhang, MS, Genevive Hernandez, PhD, Antonia Kwan, MD PhD MRCPCH, Laura Sun, PhD, Joanne I Adamkewicz, PhD, Hong Wang, MD PhD DABT, Natalie Dimier, PhD, Sue-Zen Lim, BPharm, Carol O'Hear, MD PhD, Laurie H Sehn, MD, Ian W. Flinn, MD PhD, Sung-Soo Yoon, MD PhD, Lihua E Budde, MD PhD, Chunze Li, PhD, Michael C Wei, MD PhD

Blood (2019) 134 (Supplement_1): 1285.

https://doi.org/10.1182/blood-2019-123961

Published: 2019

Journal Articles

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Kazuya Sakai, MD, Masataka Kuwana, Hiroto Kojima, Hidenori Tanaka, Masayuki Kubo, Hideo Yagi, Masanori Matsumoto

Blood (2019) 134 (Supplement_1): 1085.

https://doi.org/10.1182/blood-2019-123927

Published: 2019

Journal Articles

Impact of Human Leukocyte Antigen on the Risk of Stroke in Patients with Sickle Cell Disease

Huda Al-Harrasi, MD, Murtadha Al-Khabori, MD, Salam Al-Kindi, MD, Yasser Ahmed Mohamed Soliman Wali, MD, Mohamed Al Huneini, MD, Hamad Al-Riyami, PhD

Blood (2019) 134 (Supplement_1): 4831.

https://doi.org/10.1182/blood-2019-125038

Published: 2019

Journal Articles

Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4085.

https://doi.org/10.1182/blood-2019-129347

Published: 2019

Journal Articles

R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results

Nelly G Gabeeva, PhD, Darya A Koroleva, Svetlana A Tatarnikova, Anna K Smolyaninova, Svetlana Smirnova, MD PhD, Elena E Nikulina, Alla M. Kovrigina, MD PhD, Andrey B Sudarikov, PhD DSc, Eugene E. Zvonkov, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5334.

https://doi.org/10.1182/blood-2019-127944

Published: 2019

Journal Articles

The First Experience of Treatment of Patients with Primary Mediastinal Lymphoma Using the R-m-NHL-BFM-90/R-EPOCH Protocol

Nelly Gabeeva, PhD, Daria Koroleva, Anastasya Belyaeva, Anna Smolyaninova, Natalia G. Chernova, MD PhD, Valery Lapin, Alla M. Kovrigina, MD PhD, Eugene E. Zvonkov, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2018) 132 (Supplement 1): 5391.

https://doi.org/10.1182/blood-2018-99-115080

Published: 2018

Journal Articles

Characterization of Philadelphia-Negative Myeloproliferative Neoplasms in the Chilean Public Health System: Multicentric Study

Ximena Valladares, MD, Christine Rojas, MD, Camila Peña, MD, Claudia Gajardo, MD, Maria Elena Cabrera, MD, Rodrigo Valenzuela, PhD, Virginia Monardes, Hernán López-Vidal, MD, Marcelo Abarca, MD, Pilar León, MD, Rocío Osorio, MD, Erika Pérez, MD, Pablo Soto, MD, Gabriel La Rocca, MD, Daniela Cardemil, MD, Marvila Intriago, MD, Vivianne Torres, MD

Blood (2018) 132 (Supplement 1): 5479.

https://doi.org/10.1182/blood-2018-99-117610

Published: 2018

Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, MD PhD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, PhDMD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Tomáš Papajik, MD PhD, Gianluca Gaidano, MD PhD, Marc Andre, MD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Sumeet Ambarkhane, MD, Johannes Weirather, PhD, Maren Dirnberger-Hertweck, PhD, Kami J. Maddocks, MD

Blood (2017) 130 (Supplement 1): 4123.

https://doi.org/10.1182/blood.V130.Suppl_1.4123.4123

Published: 2017

Journal Articles

Risk Factors of Central Nervous System Involvement in Diffuse Large B-Cell Lymphoma Patients: Single Center Experience

Mahmoud Husni Hajyousef, MD, Associate Professor, Tariq Zuheir Kewan, MD, Deeb Jamil Zahran, MD, Sohaib Mahmoud Al-Khatib, MD

Blood (2017) 130 (Supplement 1): 5227.

https://doi.org/10.1182/blood.V130.Suppl_1.5227.5227

Published: 2017

Journal Articles

Risk of Central Nervous System Relapse in Patient with Peripheral T-Cell Lymphoma: Absolute Lymphocytes Count and Lymphocytes Percent at Diagnosis As Predictors

Tariq Zuheir Kewan, MD, Mahmoud Husni Hajyousef, MD, Associate Professor, Deeb Jamil Zahran, MD, Sohaib Mahmoud Al-Khatib, MD

Blood (2017) 130 (Supplement 1): 5185.

https://doi.org/10.1182/blood.V130.Suppl_1.5185.5185

Published: 2017

Journal Articles

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Sarah Bertoli, MD PhD, Suzanne Tavitian, MD, Francoise Huguet, MD, Muriel Picard, MD, Francois Vergez, DVM, PhD, Eric Delabesse, MD PhD, Audrey Sarry, Emilie Berard, MD, Christian Recher, MD PhD

Blood (2017) 130 (Supplement 1): 3903.

https://doi.org/10.1182/blood.V130.Suppl_1.3903.3903

Published: 2017

Journal Articles

Pre-PMF emerging as important subgroup of MPN

Heinz Gisslinger

Blood (2017) 129 (24): 3142–3144.

https://doi.org/10.1182/blood-2017-04-777805

Published: 2017

Journal Articles

Variation of Red Blood Cell Rheology and Adhesiveness during Vaso-Occlusive Crises in Sickle Cell Patients

Regine Hierso, PhD, Claudine Lapoumeroulie, PhD, Philippe Connes, PhD, Sara El Hoss, Catia Oliveira, Sylvie Cochet, Yves Colin Aronovicz, PhD, Caroline Le Van Kim, PhD, Marc Romana, PhD, Marie Dominique Hardy-Dessources, PhD

Blood (2016) 128 (22): 1311.

https://doi.org/10.1182/blood.V128.22.1311.1311

Published: 2016

Journal Articles

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

Ayed O. Ayed, MD, Annalisa Chiappella, MD, Grzegorz S. Nowakowski, MD, Federica Cavallo, MD, Angela Giovanna Congiu, MD, Gianluca Gaidano, MD PhD, Levi Pederson, Betsy R. Laplant, MS, William R. Macon, MD, Gerardo Musuraca, MD, Alessandro Re, MD, Michele Spina, Thomas E. Witzig, MD, Umberto Vitolo

Blood (2016) 128 (22): 3033.

https://doi.org/10.1182/blood.V128.22.3033.3033

Published: 2016

Journal Articles

The Sil Index Is a Useful Prognostic Indicator for Diffuse Large B-Cell Lymphoma

Blood (2015) 126 (23): 1512.

https://doi.org/10.1182/blood.V126.23.1512.1512

Published: 2015

Journal Articles

Higher Expression of Suppressor of Cytokine Signaling1 ( SOCS1 ) in the Bone Marrow Is an Unfavorable Prognostic Factor in Adult Patients with De Novo Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, Hwei-Fang Tien, MD PhD, Hsin-An Hou, MD PhD, Wen-Chien Chou, MD PhD, Yan-Jun Lai, Yuan-Yeh Kuo, PhD, Chien-Yuan Chen, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Shang-Yi Huang, Bor-Sheng Ko, MD PhD, Szu-Chun Hsu, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Yao-Chang Chen, MDPhD, Mei-Hsuan Tseng, Chi-Fei Huang

Blood (2014) 124 (21): 1034.

https://doi.org/10.1182/blood.V124.21.1034.1034

Published: 2014

Journal Articles

Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study

Blood (2014) 124 (21): 5979.

https://doi.org/10.1182/blood.V124.21.5979.5979

Published: 2014

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

Journal Articles

Peripheral Blood Lymphocyte/Monocyte Ratio At 6 Months After Remission As a Predictor Of Relapse After R-CHOP Therapy In Patients With Diffuse Large B-Cell Lymphoma

Blood (2013) 122 (21): 4316.

https://doi.org/10.1182/blood.V122.21.4316.4316

Published: 2013

Journal Articles

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

Yasuko Hamada, MD, Mariko Ishibashi, PhD, Toshio Asayama, MD, Namiko Okuyama, MD, Asaka Kondo, MD, PhD, Keiichi Moriya, MD, PhD, Hideya Hyodo, MD, PhD, Takehito Igarashi, MD, PhD, Hiroyuki Onose, MD, PhD, Norio Yokose, MD, PhD, Sakae Tanosaki, MD, PhD, Kazuo Shimizu, MD, PhD, Hideto Tamura, MD, PhD, Koiti Inokuchi, MD, PhD

Blood (2013) 122 (21): 4320.

https://doi.org/10.1182/blood.V122.21.4320.4320

Published: 2013

NARROW

Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Impact of Human Leukocyte Antigen on the Risk of Stroke in Patients with Sickle Cell Disease

R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results

The First Experience of Treatment of Patients with Primary Mediastinal Lymphoma Using the R-m-NHL-BFM-90/R-EPOCH Protocol

Characterization of Philadelphia-Negative Myeloproliferative Neoplasms in the Chilean Public Health System: Multicentric Study

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Risk Factors of Central Nervous System Involvement in Diffuse Large B-Cell Lymphoma Patients: Single Center Experience

Risk of Central Nervous System Relapse in Patient with Peripheral T-Cell Lymphoma: Absolute Lymphocytes Count and Lymphocytes Percent at Diagnosis As Predictors

Is Hydroxyurea Deleterious in Patients with ELN Favorable AML and WBC Inferior to 50.10 9 /L?

Pre-PMF emerging as important subgroup of MPN

Variation of Red Blood Cell Rheology and Adhesiveness during Vaso-Occlusive Crises in Sickle Cell Patients

Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies

The Sil Index Is a Useful Prognostic Indicator for Diffuse Large B-Cell Lymphoma

Higher Expression of Suppressor of Cytokine Signaling1 ( SOCS1 ) in the Bone Marrow Is an Unfavorable Prognostic Factor in Adult Patients with De Novo Acute Myeloid Leukemia

Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Peripheral Blood Lymphocyte/Monocyte Ratio At 6 Months After Remission As a Predictor Of Relapse After R-CHOP Therapy In Patients With Diffuse Large B-Cell Lymphoma

Clinicopathological Characteristics and A20 (TNFAIP3) Mutation In Primary Thyroid Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only